Seeking Alpha

Lively debate on Star Scientific

  • The situation at Star Scientific (STSI +0.9%) is bleak, according to SA contributor Paulo Santos.
  • He thinks the company's desperate measure to raise capital through the issuance of new shares is just buying time with hopes for a revenue bonanza fading.
  • The bull case on STSI hinges on the potential for Anatabloc to be a mass market product. The company expects a patent related to the treatment's active ingredient to be granted shortly.
From other sites
Comments (1)
  • Adaminatree
    , contributor
    Comments (17) | Send Message
     
    I wouldn't be holding my breath.
    16 Oct 2013, 10:03 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs